Paul Richardson, MD: Three-drug regimen for multiple myeloma

December 15, 2015

Dr. Paul Richardson of Harvard’s Dana-Farber Cancer Institute reviews the recent Lancet article by Cavo, et al, that was the first randomized controlled trial to compare three-drug regimen (bortezomib plus thalidomide plus dexamethasone) to just thalidomide/dexamethasone. The complete response rates and progression free survival were significantly better in the three drug arm.

This entry was posted in - Biotech, - Pharma, Harvard, Oncology. Bookmark the permalink.

Leave a Reply